
Terns Pharmaceuticals (TERN) Stock Forecast & Price Target
Terns Pharmaceuticals (TERN) Analyst Ratings
Bulls say
Terns Pharmaceuticals Inc. has enhanced its probability of success for its lead product candidate, TERN-701, increasing it from 40% to 60% due to a compelling data profile that promises earlier and broader adoption. The company's strong financial position, with capital support extending into 2028, combined with multiple upcoming catalysts and clinical differentiation, signifies a promising horizon for potential re-rating in stock value. Additionally, the company boasts a robust intellectual property portfolio with protections lasting until at least 2039, further strengthening the outlook for long-term value creation.
Bears say
Terns Pharmaceuticals Inc faces significant challenges that contribute to a negative outlook on its stock. Key risks include the potential failure of ongoing and future clinical trials, delays in regulatory approvals, and the possibility of unforeseen safety concerns, which could adversely affect the company's product pipeline and resulting market opportunities. Additionally, financial pressures, such as cash requirements and the risk of dilution, further compound these issues, presenting substantial hurdles to achieving the company's strategic objectives.
This aggregate rating is based on analysts' research of Terns Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Terns Pharmaceuticals (TERN) Analyst Forecast & Price Prediction
Start investing in Terns Pharmaceuticals (TERN)
Order type
Buy in
Order amount
Est. shares
0 shares